SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : momo-T/FIF -- Ignore unavailable to you. Want to Upgrade?


To: Biotech Jim who wrote (11524)2/4/2018 6:41:13 PM
From: Miljenko Zuanic  Respond to of 12215
 
Jim, I hear you. I am with you.

If stars and planets are in their favor, there are still rooms (multiple) to make decaint return.

Both compound (molecules) are not that difficult, so... CMC, manufacturing, and long term animal tox are in their reach. Rest is up to the partner, IF any!

<We should have transferred our REGN assets into VKTX in June 2017, or earlier. My bad decision still pisses me off. (I guess I succumb to altruism bias, see:>

As I said early, I bread more comfortably when I recover my initial bets (investments). REGN become victim of their own success (better said luck), but right now trend is not final. Maybe they may become "victim" of the luck, again?



To: Biotech Jim who wrote (11524)2/8/2018 10:47:02 AM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 12215
 
RE: MDGL
finance.yahoo.com

Results are in line with the class-drug expectation (including VKTX drug), and add to overall NASH benefit. because NASH subjects would be obesy, TD2, and hyperlipidemic, ...drug profile for MFGL and VKTX are in line with market needs.